Kristiyana Kaneva

Dr. Kristiyana Kaneva serves as a Senior Medical Director, Oncology Early Development at AbbVie, advancing novel molecules from discovery through phase 1 clinical trials for both hematologic malignancies and solid tumors. She was previously the Executive Medical Director of Clinical Development at Tempus AI where she worked for 5 years and lead a team that brought a solid tumor ctDNA MRD assay from a concept to the clinic. Dr. Kaneva completed her Pediatric Hematology Oncology fellowship at Children’s Hospital Los Angeles followed by an advanced fellowship in Pediatric Neuro-Oncology at Northwestern University/Ann & Robert H. Lurie Children’s Hospital of Chicago. During fellowship she studied the role of mitochondrial DNA (mtDNA) mutations in pediatric malignancies. Dr. Kaneva is a recipient of the T32 NIH grant, Ruth L. Kirschstein Institutional National Research Service Award which was appointed in August 2017 for her work on molecular targets for cancer diagnosis and surveillance in pediatric malignancies. She earned her medical degree from Loyola University Chicago Stritch School of Medicine followed by a masters of science in Clinical, Biomedical and Translational Investigations from University of Southern California. Dr. Kaneva holds a faculty appointment as a Clinical Assistant Professor at Rosalind Franklin University of Medicine and Science.